The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

This study (SUGAR Study) tests whether combining stereotactic body radiation therapy (SBRT — a highly precise form of radiation) with relugolix (an oral hormone-blocking drug) improves treatment outcomes for men with favorable intermediate-risk prostate cancer who have a high genomic risk score. **You may be eligible if...** - You are 18 or older (male or born male with a prostate, not on testosterone suppression) - You have confirmed adenocarcinoma of the prostate with Gleason score 3+4 (and PSA < 20) or Gleason 3+3 (and PSA 10–20) - Your Decipher Genomic Classifier score is 0.6 or higher (indicating high genomic risk) - Your prostate volume is 80 cc or less - Your testosterone and PSA are within required ranges **You may NOT be eligible if...** - You have had prior prostate surgery or radiation - You have confirmed metastatic disease - You have a history of long QT syndrome, significant heart rhythm abnormalities, or take QT-prolonging medications - You have ulcerative colitis or other inflammatory bowel disease - You are allergic to relugolix Talk to your doctor to see if this trial is right for you.